Literature DB >> 21964510

Colon cancer survival with herbal medicine and vitamins combined with standard therapy in a whole-systems approach: ten-year follow-up data analyzed with marginal structural models and propensity score methods.

Michael McCulloch1, Michael Broffman, Mark van der Laan, Alan Hubbard, Lawrence Kushi, Donald I Abrams, Jin Gao, John M Colford.   

Abstract

Although localized colon cancer is often successfully treated with surgery, advanced disease requires aggressive systemic therapy that has lower effectiveness. Approximately 30% to 75% of patients with colon cancer use complementary and alternative medicine (CAM), but there is limited formal evidence of survival efficacy. In a consecutive case series with 10-year follow-up of all colon cancer patients (n = 193) presenting at a San Francisco Bay-Area center for Chinese medicine (Pine Street Clinic, San Anselmo, CA), the authors compared survival in patients choosing short-term treatment lasting the duration of chemotherapy/radiotherapy with those continuing long-term. To put these data into the context of treatment responses seen in conventional medical practice, they also compared survival with Pan-Asian medicine + vitamins (PAM+V) with that of concurrent external controls from Kaiser Permanente Northern California and California Cancer Registries. Kaplan-Meier, traditional Cox regression, and more modern methods were used for causal inference-namely, propensity score and marginal structural models (MSMs), which have not been used before in studies of cancer survival and Chinese herbal medicine. PAM+V combined with conventional therapy, compared with conventional therapy alone, reduced the risk of death in stage I by 95%, stage II by 64%, stage III by 29%, and stage IV by 75%. There was no significant difference between short-term and long-term PAM+V. Combining PAM+V with conventional therapy improved survival, compared with conventional therapy alone, suggesting that prospective trials combining PAM+V with conventional therapy are justified.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21964510      PMCID: PMC4081504          DOI: 10.1177/1534735411406539

Source DB:  PubMed          Journal:  Integr Cancer Ther        ISSN: 1534-7354            Impact factor:   3.279


  102 in total

1.  Chilean propolis: antioxidant activity and antiproliferative action in human tumor cell lines.

Authors:  A Russo; V Cardile; F Sanchez; N Troncoso; A Vanella; J A Garbarino
Journal:  Life Sci       Date:  2004-12-17       Impact factor: 5.037

2.  Curcumin-induced apoptosis of human colon cancer colo 205 cells through the production of ROS, Ca2+ and the activation of caspase-3.

Authors:  Chin-Cheng Su; Jaung-Geng Lin; Te-Mao Li; Jing-Gung Chung; Jai-Sing Yang; Siu-Wan Ip; Wen-Chuan Lin; Guang-Wei Chen
Journal:  Anticancer Res       Date:  2006 Nov-Dec       Impact factor: 2.480

3.  Effects produced by Royal Jelly on haematopoiesis: relation with host resistance against Ehrlich ascites tumour challenge.

Authors:  Claudia Bincoletto; Samara Eberlin; Camila A V Figueiredo; Marcos B Luengo; Mary L S Queiroz
Journal:  Int Immunopharmacol       Date:  2005-04       Impact factor: 4.932

Review 4.  The neuropharmacology of L-theanine(N-ethyl-L-glutamine): a possible neuroprotective and cognitive enhancing agent.

Authors:  Pradeep J Nathan; Kristy Lu; M Gray; C Oliver
Journal:  J Herb Pharmacother       Date:  2006

5.  Inhibition of bleomycin lung toxicity by N-acetyl cysteine in the rat.

Authors:  N Berend
Journal:  Pathology       Date:  1985-01       Impact factor: 5.306

6.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

7.  Cigarette smoking and colorectal carcinoma mortality in a cohort with long-term follow-up.

Authors:  Laura A Colangelo; Susan M Gapstur; Peter H Gann; Alan R Dyer
Journal:  Cancer       Date:  2004-01-15       Impact factor: 6.860

Review 8.  Reducing the incidence and mortality of colon cancer: mass screening and colonoscopic polypectomy.

Authors:  Mitchell S Cappell
Journal:  Gastroenterol Clin North Am       Date:  2008-03       Impact factor: 3.806

Review 9.  Theanine and glutamate transporter inhibitors enhance the antitumor efficacy of chemotherapeutic agents.

Authors:  Tomomi Sugiyama; Yasuyuki Sadzuka
Journal:  Biochim Biophys Acta       Date:  2003-12-05

Review 10.  Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration.

Authors:  Jan P Vandenbroucke; Erik von Elm; Douglas G Altman; Peter C Gøtzsche; Cynthia D Mulrow; Stuart J Pocock; Charles Poole; James J Schlesselman; Matthias Egger
Journal:  PLoS Med       Date:  2007-10-16       Impact factor: 11.069

View more
  17 in total

1.  Verteporfin enhances the sensitivity of LOVO/TAX cells to taxol via YAP inhibition.

Authors:  Ganggang Shi; Hao Wang; Hongqiu Han; Jianchen Gan; Hui Wang
Journal:  Exp Ther Med       Date:  2018-07-16       Impact factor: 2.447

2.  Association Between Use of Traditional Chinese Medicine Herbal Therapy and Survival Outcomes in Patients With Stage II and III Colorectal Cancer: A Multicenter Prospective Cohort Study.

Authors:  Yun Xu; Jun J Mao; Lingyun Sun; Lin Yang; Jie Li; Yingxu Hao; Huashan Li; Wei Hou; Yuping Chu; Yu Bai; Xiaoqiang Jia; Jinwan Wang; Lin Shen; Ying Zhang; Jianbin Wang; Jianping Liu; Yufei Yang
Journal:  J Natl Cancer Inst Monogr       Date:  2017-11-01

3.  Can we demonstrate that breast cancer "integrative oncology" is effective? A methodology to evaluate the effectiveness of integrative oncology offered in community clinics.

Authors:  Leanna J Standish; Erin Sweet; Eleonora Naydis; M Robyn Andersen
Journal:  Integr Cancer Ther       Date:  2012-06-27       Impact factor: 3.279

4.  Celastrol inhibits colon cancer cell proliferation by downregulating miR-21 and PI3K/AKT/GSK-3β pathway.

Authors:  Haoliang Ni; Yuejun Han; Xihan Jin
Journal:  Int J Clin Exp Pathol       Date:  2019-03-01

5.  Fine-tuning vitamin E-containing telodendrimers for efficient delivery of gambogic acid in colon cancer treatment.

Authors:  Wenzhe Huang; Xu Wang; Changying Shi; Dandan Guo; Gaofei Xu; Lili Wang; Alexa Bodman; Juntao Luo
Journal:  Mol Pharm       Date:  2015-03-02       Impact factor: 4.939

6.  Meta-Analysis of Oxaliplatin-Based Chemotherapy Combined With Traditional Medicines for Colorectal Cancer: Contributions of Specific Plants to Tumor Response.

Authors:  Menghua Chen; Brian H May; Iris W Zhou; Charlie C L Xue; Anthony L Zhang
Journal:  Integr Cancer Ther       Date:  2015-08-06       Impact factor: 3.279

7.  Therapeutic applications of herbal medicines for cancer patients.

Authors:  Shu-Yi Yin; Wen-Chi Wei; Feng-Yin Jian; Ning-Sun Yang
Journal:  Evid Based Complement Alternat Med       Date:  2013-07-11       Impact factor: 2.629

8.  Survival Analysis of Advanced Non-Small Cell Lung Cancer Patients Treated by Using Wheel Balance Cancer Therapy.

Authors:  Jongmin Kim; Chong-Kwan Cho; Hwa-Seung Yoo
Journal:  Integr Cancer Ther       Date:  2016-05-04       Impact factor: 3.279

9.  Immune-system-dependent anti-tumor activity of a plant-derived polyphenol rich fraction in a melanoma mouse model.

Authors:  A Gomez-Cadena; C Urueña; K Prieto; A Martinez-Usatorre; A Donda; A Barreto; P Romero; S Fiorentino
Journal:  Cell Death Dis       Date:  2016-06-02       Impact factor: 8.469

10.  In Metastatic Non-small cell Lung Cancer Platinum-Based Treated Patients, Herbal Treatment Improves the Quality of Life. A Prospective Randomized Controlled Clinical Trial.

Authors:  Huiru Guo; Jia X Liu; Hegen Li; Jan P A Baak
Journal:  Front Pharmacol       Date:  2017-07-17       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.